A single arm phase 1b study of everolimus and sunitinib in patients with advanced renal cell carcinoma (RCC)

BACKGROUND: Everolimus ,an oral inhibitor of mammalian target of rapamycin (mTOR), and sunitinib, an oral inhibitor of VEGF/PDGF receptor tyrosine kinase signaling, have both been shown to provide clinical benefit in patients with advanced RCC. We sought to determine the safety and efficacy of combi...

Full description

Saved in:
Bibliographic Details
Published in:Clin Genitourin Cancer
Main Authors: Kanesvaran, R., Watt, K., Turnbull, J. D., Armstrong, A. J., Cohen-Wolkowiez, M., George, D. J.
Format: Artigo
Language:Inglês
Published: 2014
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4754968/
https://ncbi.nlm.nih.gov/pubmed/26174223
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2014.12.011
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items